AU2012228194B2 - Antibodies to CD70 - Google Patents

Antibodies to CD70 Download PDF

Info

Publication number
AU2012228194B2
AU2012228194B2 AU2012228194A AU2012228194A AU2012228194B2 AU 2012228194 B2 AU2012228194 B2 AU 2012228194B2 AU 2012228194 A AU2012228194 A AU 2012228194A AU 2012228194 A AU2012228194 A AU 2012228194A AU 2012228194 B2 AU2012228194 B2 AU 2012228194B2
Authority
AU
Australia
Prior art keywords
seq
antibody
human
amino acid
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012228194A
Other languages
English (en)
Other versions
AU2012228194A1 (en
Inventor
Johannes Joseph Wilhelmus De Haard
Torsten Dreier
Sofie Maria Elvire GABRIELS
Mahan Moshir
Michael John Scott Saunders
Karen Silence
Peter Ulrichts
Harald Wajant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Publication of AU2012228194A1 publication Critical patent/AU2012228194A1/en
Assigned to ARGEN-X N.V. reassignment ARGEN-X N.V. Alteration of Name(s) of Applicant(s) under S113 Assignors: ARGEN-X B.V.
Application granted granted Critical
Publication of AU2012228194B2 publication Critical patent/AU2012228194B2/en
Assigned to ARGENX BVBA reassignment ARGENX BVBA Request for Assignment Assignors: ARGEN-X N.V.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2012228194A 2011-03-16 2012-03-16 Antibodies to CD70 Active AU2012228194B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161453390P 2011-03-16 2011-03-16
US61/453,390 2011-03-16
US201161503871P 2011-07-01 2011-07-01
US61/503,871 2011-07-01
PCT/EP2012/054733 WO2012123586A1 (en) 2011-03-16 2012-03-16 Antibodies to cd70

Publications (2)

Publication Number Publication Date
AU2012228194A1 AU2012228194A1 (en) 2013-09-12
AU2012228194B2 true AU2012228194B2 (en) 2017-06-01

Family

ID=45878935

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012228194A Active AU2012228194B2 (en) 2011-03-16 2012-03-16 Antibodies to CD70

Country Status (18)

Country Link
US (7) US9765148B2 (enExample)
EP (1) EP2686347B1 (enExample)
JP (2) JP5982409B2 (enExample)
CN (1) CN103596979B (enExample)
AU (1) AU2012228194B2 (enExample)
BR (1) BR112013021562B1 (enExample)
CA (1) CA2828753C (enExample)
CY (1) CY1120471T1 (enExample)
DK (1) DK2686347T3 (enExample)
ES (1) ES2670874T3 (enExample)
HU (1) HUE039849T2 (enExample)
IL (1) IL228001B (enExample)
PL (1) PL2686347T3 (enExample)
PT (1) PT2686347T (enExample)
RU (1) RU2604196C2 (enExample)
SI (1) SI2686347T1 (enExample)
TR (1) TR201807202T4 (enExample)
WO (1) WO2012123586A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019409936B2 (en) * 2018-12-18 2025-09-11 University Of Bern CD70 and venetoclax, a BCL-2 inhibitor, combination therapy for treating acute myeloid leukemia

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08935B2 (ja) 1991-03-15 1996-01-10 新日本製鐵株式会社 線材コイルの脱水素処理装置
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
BR112013021562B1 (pt) 2011-03-16 2023-01-10 Argenx Bvba Anticorpos para cd70
SMT201900242T1 (it) * 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
WO2014176696A1 (en) * 2013-04-30 2014-11-06 Université de Montréal Novel biomarkers for acute myeloid leukemia
JP2016531920A (ja) * 2013-09-05 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ７０結合ペプチドおよびそれに関連する方法、プロセスおよび用途
US10391168B1 (en) * 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
KR102390359B1 (ko) * 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
WO2017044752A1 (en) * 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
BR112019023608A2 (pt) 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
GB2567613A (en) 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
AU2019216269B2 (en) 2018-01-30 2025-05-01 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen
MX2020008183A (es) 2018-02-01 2020-09-22 Pfizer Anticuerpos especificos para cd70 y sus usos.
MX2020008184A (es) 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.
US20200063100A1 (en) 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer
JP7649239B2 (ja) * 2018-11-30 2025-03-19 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド キメラ抗原受容体ファクトリおよびその使用方法
CA3138633A1 (en) 2019-04-30 2020-11-05 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
RU2738802C1 (ru) * 2019-08-21 2020-12-17 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
AU2020382219A1 (en) 2019-11-13 2022-05-12 Crispr Therapeutics Ag Manufacturing process for making T cells expressing chimeric antigen receptors
BR112022013445A2 (pt) * 2020-01-08 2022-09-13 Univ Texas Método de modificação de células exterminadoras naturais para direcionar tumores cd70-positivos
CN111909966B (zh) * 2020-04-01 2021-09-21 苏州克睿基因生物科技有限公司 一种制备经修饰的免疫细胞的方法
EP4173638A1 (en) * 2020-06-30 2023-05-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cd70 antibody and application thereof
EP4189395A1 (en) 2020-07-28 2023-06-07 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for preventing and treating a cancer
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
US20240024475A1 (en) 2020-12-01 2024-01-25 Cure Genetics Co., Ltd Antigen-Binding Protein Targeting CD70 and Use Thereof
CN114685657B (zh) * 2020-12-31 2024-08-16 康诺亚生物医药科技（成都）有限公司 一种功能增强型抗体阻断剂的开发及其应用
CN115260303B (zh) * 2021-05-31 2025-04-22 百奥赛图(北京)医药科技股份有限公司 Cd70基因人源化非人动物的构建方法及应用
CN113292653B (zh) * 2021-06-17 2022-11-11 南京蓝盾生物科技有限公司 具有增强的adcp效应的抗cd70抗体及其应用
CN113754769B (zh) * 2021-10-13 2023-06-06 宜明昂科生物医药技术（上海）股份有限公司 靶向cd70的抗体及其制备和用途
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
TWI871168B (zh) * 2023-01-16 2025-01-21 大陸商上海華奧泰生物藥業股份有限公司 靶向cd70的抗體或結合cd70的抗原結合片段及其製備方法和應用
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113909A2 (en) * 2005-04-19 2006-10-26 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
US20030148321A1 (en) 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
EP1470247A2 (en) 2001-11-05 2004-10-27 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
NZ533240A (en) 2001-11-27 2007-12-21 Oxford Glycosciences Uk Ltd Use of polypeptide for the treatment of epithelial-derived cancer
US7261892B2 (en) 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
DE602004028347D1 (de) 2003-03-24 2010-09-09 Zymogenetics Inc Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
SG188175A1 (en) * 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006044643A2 (en) 2004-10-15 2006-04-27 Seattle Genetics, Inc. Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
EA015706B1 (ru) 2004-10-22 2011-10-31 Займоджинетикс, Инк. Моноклональное антитело или его фрагмент, связывающиеся с полипептидом il-22ra, гуманизированное антитело, полученное из указанного антитела, гибридомы, продуцирующие антитело, и применение указанного антитела
WO2006113747A2 (en) 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US20080280297A1 (en) 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
CN101370830A (zh) * 2005-09-26 2009-02-18 米德列斯公司 抗cd70的人单克隆抗体
EP1934261B1 (en) 2005-09-26 2014-10-29 Medarex, L.L.C. Human monoclonal antibodies to cd70
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
PL2099823T5 (pl) * 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
AR062123A1 (es) * 2007-07-27 2008-10-15 Inst Nac De Tecnologia Agropec Dominio vhh monomerico derivado de anticuerpos de camelidos anti-vp6 dominio dimerico, metodo de inmunodeteccion de rotavirus, composiciones, metodos de prevencion y tratamiento de infecciones con rotavirus
KR100807069B1 (ko) 2007-09-21 2008-02-25 고려대학교 산학협력단 암 치료용 의약 조성물
AU2008324203A1 (en) 2007-11-05 2009-05-14 Novartis Ag Methods and compositions for measuring Wnt activation and for treating Wnt-related cancers
ES2588194T3 (es) * 2008-04-11 2016-10-31 Seattle Genetics, Inc. Detección y tratamiento de cáncer pancreático, de ovario y otros cánceres
EP2297301A1 (en) 2008-05-28 2011-03-23 U-Protein Express B.V. Method for the production of proteins or protein fragments
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010014948A1 (en) 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
WO2010019921A2 (en) 2008-08-15 2010-02-18 The Regents Of The University Of California Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
CA2747644C (en) * 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
ES2835553T3 (es) 2009-08-10 2021-06-22 Biosplice Therapeutics Inc Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos
WO2011035433A1 (en) 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
MX2012005791A (es) 2009-11-19 2012-07-03 Merck Serono Sa Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana.
AU2010339359A1 (en) 2009-12-29 2012-07-26 Kyowa Hakko Kirin Co., Ltd. Anti-CD27 antibody
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
JP5940093B2 (ja) 2011-01-19 2016-06-29 カンタージア アクチエボラーグ 抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用
BR112013021562B1 (pt) 2011-03-16 2023-01-10 Argenx Bvba Anticorpos para cd70
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
AP2014007588A0 (en) 2011-09-22 2014-04-30 Amgen Inc CD27L antigen binding proteins
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
WO2013093508A2 (en) 2011-12-22 2013-06-27 Oslo University Hospital Hf Wnt pathway inhibitors
JO3787B1 (ar) 2012-03-15 2021-01-31 Janssen Biotech Inc أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها
US20150086521A1 (en) 2012-03-21 2015-03-26 Erytech Pharma Medicament for the Treatment of Acute Myeloid Leukemia (AML)
US9801851B2 (en) 2012-05-23 2017-10-31 St. Jude Children's Research Hospital Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias
RU2627712C2 (ru) 2012-06-15 2017-08-10 Кьюрдженикс Инк. Соединение как ингибитор передачи сигналов wnt, его композиции и применение
AU2013310924B2 (en) 2012-08-31 2017-08-03 Argenx Bvba Method for producing antibody molecules having inter-species, intra-target cross-reactivity
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
US20150315279A1 (en) 2012-12-21 2015-11-05 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
DK2956173T3 (en) 2013-02-14 2017-07-17 Bristol Myers Squibb Co TUBULYSIS RELATIONSHIPS, METHODS OF PRODUCING AND USING THEREOF
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
EP3125645A1 (en) 2015-07-31 2017-02-01 Bleckmann GmbH & Co. KG Flange assembly for securing a heating device to a fluid container
WO2017044752A1 (en) 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
GB2567613A (en) 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113909A2 (en) * 2005-04-19 2006-10-26 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019409936B2 (en) * 2018-12-18 2025-09-11 University Of Bern CD70 and venetoclax, a BCL-2 inhibitor, combination therapy for treating acute myeloid leukemia

Also Published As

Publication number Publication date
RU2604196C2 (ru) 2016-12-10
HUE039849T2 (hu) 2019-02-28
SI2686347T1 (en) 2018-08-31
CN103596979B (zh) 2018-01-26
PT2686347T (pt) 2018-07-05
JP2014509861A (ja) 2014-04-24
US20140141016A1 (en) 2014-05-22
TR201807202T4 (tr) 2018-06-21
US20140147450A1 (en) 2014-05-29
US9765149B2 (en) 2017-09-19
JP6261651B2 (ja) 2018-01-17
US20170369581A9 (en) 2017-12-28
EP2686347B1 (en) 2018-05-02
US11072665B2 (en) 2021-07-27
CA2828753A1 (en) 2012-09-20
US11434298B2 (en) 2022-09-06
BR112013021562B1 (pt) 2023-01-10
CY1120471T1 (el) 2019-07-10
CN103596979A (zh) 2014-02-19
IL228001B (en) 2018-06-28
ES2670874T3 (es) 2018-06-01
DK2686347T3 (en) 2018-06-25
US9765148B2 (en) 2017-09-19
EP2686347A1 (en) 2014-01-22
IL228001A0 (en) 2013-09-30
JP5982409B2 (ja) 2016-09-07
US8834882B2 (en) 2014-09-16
JP2016196471A (ja) 2016-11-24
US20260042856A1 (en) 2026-02-12
US20140235843A1 (en) 2014-08-21
CA2828753C (en) 2022-07-26
US20150266963A1 (en) 2015-09-24
WO2012123586A1 (en) 2012-09-20
PL2686347T3 (pl) 2018-10-31
AU2012228194A1 (en) 2013-09-12
US20190270823A1 (en) 2019-09-05
US20230265201A1 (en) 2023-08-24
RU2013146106A (ru) 2015-04-27
BR112013021562A2 (pt) 2016-11-08

Similar Documents

Publication Publication Date Title
US20260042856A1 (en) Antibodies to cd70
AU2011325097B2 (en) Anti c-Met antibodies
US20160207996A1 (en) Antibodies to complex targets
US10696741B2 (en) Anti-IL-22R antibodies
AU2021359092A1 (en) Binding molecules that multimerise cd45
GB2543729A (en) Antibodies to IL-24

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ARGENX BVBA

Free format text: FORMER OWNER(S): ARGEN-X N.V.